1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Small-Cell Lung Cancer - Drugs In Development, 2022, provides an overview of the Small-Cell Lung Cancer (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Small cell lung cancer (SCLC) is a fast-growing type of lung cancer. It spreads much more quickly than non-small cell lung cancer. SCLC is the most aggressive form of lung cancer. It usually starts in the breathing tubes (bronchi) in the center of the chest. These tumors often spread rapidly (metastasize) to other parts of the body, including the brain, liver, and bone. Symptoms of SCLC include bloody sputum, chest pain, cough, loss of appetite, weight loss and wheezing. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Small-Cell Lung Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Small-Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Small-Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Small-Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 18, 128, 77, 14, 72, 20 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 3 and 1 molecules, respectively.
Small-Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Small-Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Small-Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Small-Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Small-Cell Lung Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Small-Cell Lung Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Small-Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Small-Cell Lung Cancer - Overview
- Small-Cell Lung Cancer - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Small-Cell Lung Cancer - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Small-Cell Lung Cancer - Companies Involved in Therapeutics Development
- Small-Cell Lung Cancer - Drug Profiles
- Small-Cell Lung Cancer - Dormant Projects
- Small-Cell Lung Cancer - Discontinued Products
- Small-Cell Lung Cancer - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- Number of Products under Development for Small-Cell Lung Cancer, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Small-Cell Lung Cancer - Dormant Projects, 2022
- Small-Cell Lung Cancer - Discontinued Products, 2022
- Number of Products under Development for Small-Cell Lung Cancer, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 23andMe Holding Co.
- Abbisko Cayman Limited
- AbbVie Inc
- ADC Therapeutics SA
- Advanced Accelerator Applications SA
- Advenchen Laboratories LLC
- Aeglea BioTherapeutics Inc
- Aileron Therapeutics Inc
- Akeso Inc
- Algernon Pharmaceuticals Inc
- Alkermes Plc
- Allogene Therapeutics Inc
- Alphamab Oncology
- Amgen Inc
- Amphivena Therapeutics Inc
- Andarix Pharmaceuticals Inc
- Apollomics Inc
- Applied Research using OMIC Sciences SL
- Arcellx Inc
- Ariceum Therapeutics GmbH
- Ascenta Therapeutics Inc
- Ascentage Pharma Group International
- Ascentawits Pharmaceuticals Ltd
- Astellas Pharma Inc
- Astex Pharmaceuticals Inc
- AstraZeneca Plc
- Athenex Inc
- Auransa Inc
- Autolus Therapeutics Plc
- Bavarian Nordic AS
- Bayer AG
- BeiGene Ltd
- Beta Pharma Inc
- Betta Pharmaceuticals Co Ltd
- BeyondSpring Inc
- Bio-Thera Solutions Ltd
- BioAtla Inc
- Biogenera SpA
- BioLineRx Ltd
- BioNTech SE
- Biotheus Inc
- Boehringer Ingelheim International GmbH
- Bolt Biotherapeutics Inc
- BrightGene Bio-Medical Technology Co Ltd
- Bristol-Myers Squibb Co
- C4 Therapeutics Inc
- Calithera Biosciences Inc
- Cardiff Oncology Inc
- Carrick Therapeutics Ltd
- Celcuity Inc
- Celldex Therapeutics Inc
- Centrymed Pharmaceutical Inc
- Checkpoint Therapeutics Inc
- Chia Tai Tianqing Pharmaceutical Group Co Ltd
- Chimeric Therapeutics Ltd
- Chiome Bioscience Inc
- Clarity Pharmaceuticals Ltd
- Compass Therapeutics Inc
- Cotinga Pharmaceuticals Inc
- CSPC Pharmaceutical Group Ltd
- CStone Pharmaceuticals Co Ltd
- Culnexin Therapeutics LLC
- Curis Inc
- Cybrexa Inc
- Cyclacel Pharmaceuticals Inc
- Cyteir Therapeutics Inc
- Daiichi Sankyo Co Ltd
- Duality Biologics (Shanghai) Co Ltd
- Dyadic International Inc
- Eisai Co Ltd
- Eli Lilly and Co
- Ellipses Pharma Ltd
- EpicentRx Inc
- EpimAb Biotherapeutics Inc
- Epizyme Inc
- Esanex Inc
- Exelixis Inc
- F. Hoffmann-La Roche Ltd
- Fate Therapeutics Inc
- FatiAbGen Corp
- Fujifilm Holdings Corp
- G1 Therapeutics Inc
- Genelux Corp
- Genexine Inc
- Genmab AS
- Genprex Inc
- GI Innovation Co Ltd
- Gilead Sciences Inc
- Glycotope GmbH
- GSK plc
- Guangdong Zhongsheng Pharmaceutical Co Ltd
- Guangzhou BeBetter Medicine Technology Co Ltd
- Guangzhou Sinogen Pharmaceutical Co Ltd
- Guangzhou Yinming Biomedical Technology Co Ltd
- Hangzhou Bensheng Pharmaceutical Co Ltd
- Hangzhou DAC Biotech Co Ltd
- Hanmi Pharmaceuticals Co Ltd
- Harpoon Therapeutics Inc
- Hibercell Inc
- Hillstream BioPharma Inc
- Horizon Therapeutics Plc
- Hutchison MediPharma Ltd
- ImaginAb Inc
- Imago BioSciences Inc
- Immatics NV
- ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
- ImmunityBio Inc
- Immunocore Holdings Plc
- IMPACT Therapeutics Inc
- Incyte Corp
- Inhibrx Inc
- Innovent Biologics Inc
- Inspirna Inc
- Ipsen SA
- Jacobio Pharmaceuticals Group Co Ltd
- JenKem Technology Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Johnson & Johnson
- JSR Life Sciences LLC
- Jubilant Therapeutics Inc
- Kartos Therapeutics Inc
- Karyopharm Therapeutics Inc
- Kezar Life Sciences Inc
- Kintor Pharmaceutical Ltd
- Kronos Bio Inc
- L&L Biopharma Co Ltd
- Lee's Pharmaceutical Holdings Ltd
- Legend Biotech Corp
- LegoChem Biosciences Inc
- Lepu Biopharma Co Ltd
- LintonPharm Co Ltd
- Lixte Biotechnology Holdings Inc
- Luye Pharma Group Ltd
- Lyvgen Biopharma Ltd
- MabVax Therapeutics Holdings Inc
- Mabwell Shanghai Bioscience Co Ltd
- MacroGenics Inc
- MAIA Biotechnology Inc
- Maxinovel Pharmaceuticals
- MaxiVAX SA
- Merck & Co Inc
- Merck KGaA
- Moderna Inc
- Mologen AG
- Monte Rosa Therapeutics Inc
- MultiVir Inc
- Nanjing CART Medical Technology Co Ltd
- Nanology LLC
- NewBio Therapeutics Inc
- Ningbo Wenda Pharmaceutical Technology Co Ltd
- Northlake International LLC
- Novartis AG
- Novelty Nobility Inc
- NOX Pharmaceuticals Inc
- Omega Therapeutics Inc
- OncoFusion Therapeutics Inc
- Oncorus Inc
- OneThree Biotech Inc
- Ono Pharmaceutical Co Ltd
- Oryzon Genomics SA
- Oxford BioTherapeutics Ltd
- Pacylex Pharmaceuticals Inc
- PCG-Biotech Co Ltd
- Pfizer Inc
- Phanes Therapeutics Inc
- Pharma Mar SA
- Pieris Pharmaceuticals Inc
- Pleco Therapeutics BV
- Plexium Inc
- Plexxikon Inc
- PNB Vesper Life Science Pvt Ltd
- Prelude Therapeutics Inc
- Processa Pharmaceuticals Inc
- ProLynx LLC
- Propanc Biopharma Inc
- Qilu Pharmaceutical Co Ltd
- Qilu Puget Sound Biotherapeutics Corp
- Qurient Co Ltd
- Rapa Therapeutics LLC
- RAPT Therapeutics Inc
- RayzeBio Inc
- Recombio SL
- Regeneron Pharmaceuticals Inc
- Rhizen Pharmaceuticals SA
- RNR BioMedical Inc
- Salubris Biotherapeutics Inc
- Sanofi
- Scancell Holdings Plc
- SciTech Development LLC
- Seagen Inc
- SELLAS Life Sciences Group Inc
- Shanghai De Novo Pharmatech Co Ltd
- Shanghai Escugen Biotechnology Co Ltd
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
- Shanghai Henlius Biotech Inc
- Shanghai Huilun Life Science & Technology Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Shanghai Yingli Pharmaceutical Co Ltd
- Shenzhen Chipscreen Biosciences Co Ltd
- Shijiazhuang Sagacity New Drug Development Co Ltd
- Sichuan J.Z. Bio-chemical Science and Technology Development Co Ltd
- Simcha Therapeutics Inc
- Sino Biopharmaceutical Ltd
- SN BioScience
- Sorrento Therapeutics Inc
- SOTIO Biotech AS
- Stcube Inc
- Suzhou Zelgen Biopharmaceutical Co Ltd
- Syros Pharmaceuticals Inc
- Takeda Pharmaceutical Co Ltd
- Targovax ASA
- Tarveda Therapeutics Inc
- Telomium SAS
- Terns Pharmaceuticals Inc
- Theratechnologies Inc
- Thetis Pharmaceuticals LLC
- Tmunity Therapeutics Inc
- Transcenta Holding Ltd
- Transcode Therapeutics Inc
- TransThera Sciences (Nanjing) Inc
- Treadwell Therapeutics Inc
- TYK Medicines Inc
- Vincerx Pharma Inc
- Wigen Biomedicine Technology (Shanghai) Co Ltd
- WindMIL Therapeutics Inc
- Woomera Therapeutics Inc
- Xbrane Biopharma AB
- Xcovery Holding Co LLC
- Xencor Inc
- Y-mAbs Therapeutics Inc
- Zensun (Shanghai) Sci & Tech Co Ltd
